多发性硬化症疾病修饰疗法清单和净价格的变化,2013年至2021年
Daniel M Hartung1, Nico Gabriel2, Walid F Gellad3
1Pharmacy Practice, Oregon State University.
Neurology. Clinical practice
|February 19, 2026
概括
由于折扣,口服多发性硬化症 (MS) 疾病修饰疗法 (DMT) 的净价格比目录价格上少. 单克隆抗体 (MAb) DMT净价格大幅上,折扣抵消了较少的价格上.
科学领域:
- 药品定价分析 药品定价分析
- 医疗保健经济学 医疗保健经济学
- 多发性硬化症的治疗方法
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
- 改变疾病的疗法 (DMT) 对于控制多发性硬化症的进展至关重要.
- 了解药品定价趋势对于患者获取和医疗保健可持续性至关重要.
研究的目的:
- 从2013年到2021年,分析品牌MS DMT的清单和净价格变化.
- 为了比较口服DMT和单克隆抗体 (MAb) DMT之间的定价趋势.
- 评估制造商折扣对药品净价格的影响.
主要方法:
- 使用的药品定价和使用数据来源.
- 品牌口服和MAb DMT的估计清单和净价格.
- 计算了经通胀调整的价格,年平均变化 (AAC) 和折扣百分比.
主要成果:
- 口服DMT的目录价格增加了5.3%AAC,而净价格由于不断增长的折扣 (6.4%-21.2%) 增加了1.5%AAC.
- MAb DMT的目录价格上了4.1%AAC,净价格上了3.0%AAC.
- 折扣抵消了口服DMT的累计清单价格上的51%-86%,而MAb DMT的0%-35%.
结论:
- 不同的净定价趋势表明口服DMT之间的竞争加剧.
- 缺乏生物类似药的选择可能会导致MAb DMTs的净价格上较高.
- 制造商折扣在缓解某些MS疗法的净价格增长方面发挥着重要作用.
相关概念视频
01:26FDA Approved Drugs: Changes to Approved Drugs
286
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
286
01:29Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
01:28Drug Products: Biologics, Biosimilars and Interchangeables
288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
24
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
24
01:22Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K